Transaction Details
The Company has completed the acquisition of 1,46,400 equity shares of ₹10 each of Yapan Bio Private Limited from its existing shareholders. The aggregate cash consideration for the acquisition was approximately ₹76 crores.
Shareholding Change
Pursuant to this acquisition, Piramal Pharma Limited's shareholding in Yapan Bio has increased from 33.33% to 74.00% of the equity share capital of Yapan Bio Private Limited.
Corporate Status Change
Consequent to this acquisition, Yapan Bio Private Limited has ceased to be an associate company and has become a subsidiary of Piramal Pharma Limited. The promoter/promoter group of Piramal Pharma Limited is deemed to be indirectly interested in Yapan Bio through the Company's investment.
Company Background
Yapan Bio Private Limited was incorporated on 11th October, 2019 under the provisions of Companies Act, 2013. The company is a Contract Development and Manufacturing Organization (CDMO) specializing in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics.
Financial Performance
Yapan Bio's revenue from operations for recent financial years:
- FY2024: ₹26.91 crores
- FY2025: ₹54.40 crores
- FY2026: ₹26.34 crores
Strategic Rationale
With this acquisition, Piramal Pharma will fully embed Yapan's advanced large molecule capabilities into its integrated service offering, enabling the Company to develop and scale complex biologic therapies with greater efficiency.